Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

In the fourth quarter of 2024, Libtayo grew sales 50% to $367 million, propelling the PD-1 treatment past the blockbuster threshold for the first time. During the full year, the drug's sales reach ...

Sales rose 10% to $3.79B, surpassing the $3.75B estimates. Eylea HD and Eylea U.S. sales grew 2% Y/Y to $1.49B, while Libtayo sales surged 50% to $367M. Sanofi collaboration revenue also increased.

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination, compared to 13 months with chemo on ...

When interest rates are low, small-cap stocks begin to shine and outpace larger companies in value. These stocks are stocks with a market capitalization between $300 million and $3 billion.

Call it foresight. Either way, the Red Wings were smart to lock up Dylan Larkin, Moritz Seider, and Lucas Raymond to long-term contracts before the salary cap jumped up significantly. Larkin and ...

Libtayo was approved by the US Food and Drug Administration (FDA) as a first-line (1L) therapy for patients with locally advanced or metastatic NSCLC with 50% or more PD-L1 expression. On World Cancer ...

The trial is testing the hypothesis that low doses of THIO administered prior to cemiplimab (Libtayo ®) will enhance and prolong immune response in patients with advanced NSCLC who previously did not ...

IPC Indice de Precios Y Cotizaciones 51,209.53-840.72-1.62% ...